ME3 - IMPACT OF COST SHARING ON TREATMENT AUGMENTATION IN PATIENTS WITH DEPRESSION
Gibson TB¹, Jing Y², Bagalman E¹, Cao Z¹, Bates J², Hebden T², Forbes RA³, Doshi JA^4
1Thomson Reuters, Ann Arbor, MI, USA, ²Bristol-Myers Squibb Company, Plainsboro, NJ, USA, ³Otsuka Pharmaceutical Development & Commercialization, Princeton, NJ, USA, ⁴University of Pennsylvania School of Medicine, Philadelphia, PA, USA

UT3 - RELIABILITY OF HEALTH UTILITIES INDEX (HUI) SCORES: PATIENT AND PARENT INTER-RATER AGREEMENT ACROSS TWO CLINICAL TRIALS OF TREATMENT FOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN CHILDHOOD

Horsman JR¹, Rae CS², Furlong W¹, Silverman LB³, Sallan SE³, Athale U², Barr RD²

¹Health Utilities Inc., Dundas, ON, Canada, ²McMaster University, Hamilton, ON, Canada, ³Harvard Medical School, Boston, MA, USA

HE2 - HEALTH CARE COSTS OF METASTATIC SQUAMOUS CELL CARCINOMA OF HEAD AND NECK - FINDINGS FROM LINKED SEER-MEDICARE DATA

Parthan A¹, Kulakodlu M², Deflin M¹, Taylor D³, Barber B⁴, Zhao Z⁴

¹i3 Innovus, San Francisco, CA, USA, ²i3 Innovus, Eden Prairie, MN, USA^{, 3}i3 Innovus, Medford, MA, USA, ⁴Amgen Inc., Thousand Oaks, CA, USA

PR2 - EVALUATING THE MEASUREMENT PROPERTIES OF AN AUGMENTED EQ-5D WITH THE INCLUSION OF TWO SINGLE QUALITY-OF-LIFE (QOL) INDICATORS USING THE MEDICAL EXPENDITURE PANEL SURVEY (MEPS)

Gu NY¹, Bond TG², Craig BM³

¹Pharmerit North America, LLC, Bethesda, MD, USA, ²James Cook University, Townsville, QLD, Australia, ³Moffitt Cancer Center, Tampa, FL, USA

UT4 - EVALUATING WILLINGNESS TO PAY THRESHOLDS FOR A DEMENTIA CAREGIVING INTERVENTION

Jutkowitz E, Gitlin L, Pizzi LT

SB4 - DEALING WITH SELECTION BIAS IN NONLINEAR SETTINGS: A CASE OF COMPARATIVE EFFECTIVENESS OF STATIN PLUS FIBRATE COMBINATION THERAPY VERSUS STATIN MONOTHERAPY IN TYPE II DIABETES

Suh HS¹, Doctor J², Hay JW³

¹National Evidence-based Healthcare Collaborating Agency (NECA), Seoul, South Korea, ²USC School of Pharmacy, Los Angeles, CA, USA, ³University of Southern California, Los Angeles, CA, USA

PM1 - RISK-BENEFIT FRAMEWORK FOR EVALUATION OF GENE EXPRESSION PROFILING IN WOMEN WITH EARLY STAGE BREAST CANCER: A DECISION MODEL DEVELOPED IN COLLABORATION WITH STAKEHOLDERS

Roth J, Veenstra D

¹University of Washington, Pharmaceutical Outcomes Research and Policy Program, Seattle, WA, USA

RM4 - CONFOUNDING EFFECT OF AGE IN THE ASSOCIATION OF CARDIOVASCULAR RISK AND DIETARY SUPPLEMENT USE AMONG US ADULTS

Yu S¹, Shaw JW¹, Crawford SY¹, Groo V²

¹University of Illinois at Chicago, Chicago, IL, USA, ²University of Illinois at Chicago, Chicago , IL, USA

CN2 - USE OF LATENT VARIABLE AND SURVIVAL MODELING TO ESTIMATE THE ASSOCIATION OF PATIENT-REPORTED OUTCOMES AND PROGRESSION-FREE SURVIVAL IN MALIGNANT PLEURAL MESOTHELIOMA

Hackshaw MD¹, Boye ME², West TM², Prehn AW¹

¹Walden University, Minneapolis, MN, USA, ²Eli Lilly and Company, Indianapolis, IN, USA

PCN13 - TAXANE USE AND NEUROPATHY IN EARLY STAGE BREAST CANCER PATIENTS – RESULTS FROM A US COMMUNITY ONCOLOGY CENTER

Zhao L¹, Seal B², Sullivan S³, Christiansen NP^4
1eTeam. Inc, South Plainfield, NJ, USA, ²Sanofi-Aventis Pharmaceuticals, Bridgewater, NJ, USA, ³University of Washington, Seattle, WA, USA, ⁴Medical University of South Carolina, Charleston, SC, USA

PND27 - CONFIRMATORY FACTOR ANALYSIS AND DIFFERENTIAL ITEM FUNCTIONING ANALYSIS OF THE MIGRAINE-SPECIFIC QUALITY OF LIFE QUESTIONNAIRE VERSION 2.1 IN CHRONIC MIGRAINEURS

Rendas-Baum R¹, Maglinte GA², DeRosa M¹, Yang M¹, Varon SF^2
1QualityMetric Incorporated, Lincoln, RI, USA, ²Allergan, Inc, Irvine, CA, USA

PSS11 - COST-UTILITY ANALYSIS OF MAINTENANCE TREATMENT WITH TACROLIMUS OINTMENT IN ADULTS AND CHILDREN WITH MODERATE AND SEVERE ATOPIC DERMATITIS

Chambers C¹, Bentley A^2
1Astellas Pharma Europe Ltd, Staines, UK, ²Abacus International, Bicester, Oxfordshire, UK

PND18 - HEALTH STATUS, RESOURCE UTILIZATION, AND WORK PRODUCTIVITY FOR CAREGIVERS OF ADULTS WITH EPILEPSY: A PROPENSITY SCORE ANALYSIS OF NATIONAL SURVEY DATA

Abouzaid S¹, DiBonaventura MD², Forlenza JB¹, Durkin MB^1
1Ortho-McNeil Janssen Scientific Affairs, LLC, Titusville, NJ, USA, ²KantarHealth, New York, NY, USA

PGI17 - COST-EFFECTIVENESS ANALYSIS OF TREATMENT WITH PEGINTERFERON-ALFA-2A VERSUS PEGINTERFERON-ALFA-2B FOR PATIENTS WITH GENOTYPES 2/3 CHRONIC HEPATITIS C UNDER THE PUBLIC PAYER PERSPECTIVE IN BRAZIL
Barros FMR¹, Cheinquer H², Borges LG³, Santos E^3
1Hospital Português de Beneficência em Pernambuco and Hospital das Clínicas - UFPE, Recife, Brazil, ²Hospital das Clínicas da Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ³Roche Brazil, São Paulo, Brazil

PHP2 - VALIDITY OF THE ADHERENCE ESTIMATOR IN THE PREDICTION OF PERSISTENCE WITH CHRNONIC MEDICATIONS ASSESSED OVER 14 MONTHS

Gadkari A, McHorney C
Merck & Co., Inc., North Wales, PA, USA

PND26 - VALIDATING USE OF THE MIGRAINE-SPECIFIC QUALITY OF LIFE QUESTIONNAIRE VERSION 2.1 (MSQ) ACROSS MIGRAINE DISORDERS

Elson CL¹, Maglinte GA², Rendas-Baum R³, DeRosa M³, Yang M³, Varon SF^2
1University of Georgia, Athens, GA, USA, ²Allergan, Inc, Irvine, CA, USA, ³QualityMetric Incorporated, Lincoln, RI, USA

PDB1 - ASSOCIATION BETWEEN GLYCOSYLATED HEMOGLOBIN AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A NESTED CASE-CONTROL STUDY

Colayco D¹, Cheetham CT², Niu F², McCombs J^1
1USC School of Pharmacy, Los Angeles, CA, USA, ²Kaiser Permanente, Downey, CA, USA

PMC17 - A COMPARISON OF THE DISCRIMINTATIVE AND EVALUATIVE PROPERTIES OF THE SF-36 AND THE SF-6D INDEX

Mutebi A¹, Brazier J², Walters S^2
1University of Arizona, Tucson, AZ, USA, ²University of Sheffield, Sheffield, UK